NG-202
Acute Myeloid Leukemia
PreclinicalActive
Key Facts
Indication
Acute Myeloid Leukemia
Phase
Preclinical
Status
Active
About Nanogen Pharmaceutical Biotechnology
South Korean biotech leveraging nanobody‑based therapeutics for oncology and immunology.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AFM28 | Affimed | Phase 1/2 |
| AML (N-Act) AI | Biostate AI | Development |
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| QL325 | QLSF Biotherapeutics | Phase 1 |
| NPM1 Testing in AML | Diatech Pharmacogenetics | Commercial |
| Joint Development for AML | Ordaos Bio | Pre-clinical |
| DFP Oncology Program | Delta-Fly Pharma | Preclinical |
| LBS-007 | Lin BioScience | Phase 1/2 |
| RG6356 (RO7434656) | Chugai Pharmaceutical | Phase III |
| AL8326 | Shanghai Allist Pharmaceuticals | Phase II |